PDF(Pubmed)
Abstract：
BACKGROUND: The BRAF p.V600E genetic variant facilitates the pathogenesis of various tumors by triggering tumor proliferation and progression. The aim of this study was to analyze the prevalence of BRAF p.V600E in benign mixed epithelial and mesenchymal and malignant odontogenic tumors. In addition, we discussed the different detection methods used to assess for aberrant BRAF.
METHODS: This systematic review followed the PRISMA guidelines and was registered in Prospero (CRD42023445689). A comprehensive search of the PubMed/MEDLINE, Scopus, Web of Science, and Embase electronic databases was performed to answer the question \"What is the prevalence of the BRAF p.V600E mutation in benign mixed and malignant odontogenic tumors?\" The methodological quality of the selected studies was assessed using the JBI\'s Critical Appraisal Tool.
RESULTS: Initially, 387 records were identified, but only 11 articles met the inclusion criteria. A total of 70 patients with benign mixed epithelial and mesenchymal odontogenic tumors and 63 with malignant odontogenic tumors were included in the analysis. We found that the BRAF p.V600E mutation had a prevalence of 31.42% in mixed tumors and 26.98% in malignant odontogenic tumors. Moreover, immunohistochemistry showed high concordance with DNA-based molecular methods.
CONCLUSIONS: In general, the BRAF p.V600E variant exhibited a prominent prevalence in mixed and malignant odontogenic tumors. However, most of the findings are based on small cohorts of patients and further studies with larger cohorts are needed.
METHODS: This systematic review followed the PRISMA guidelines and was registered in Prospero (CRD42023445689). A comprehensive search of the PubMed/MEDLINE, Scopus, Web of Science, and Embase electronic databases was performed to answer the question \"What is the prevalence of the BRAF p.V600E mutation in benign mixed and malignant odontogenic tumors?\" The methodological quality of the selected studies was assessed using the JBI\'s Critical Appraisal Tool.
RESULTS: Initially, 387 records were identified, but only 11 articles met the inclusion criteria. A total of 70 patients with benign mixed epithelial and mesenchymal odontogenic tumors and 63 with malignant odontogenic tumors were included in the analysis. We found that the BRAF p.V600E mutation had a prevalence of 31.42% in mixed tumors and 26.98% in malignant odontogenic tumors. Moreover, immunohistochemistry showed high concordance with DNA-based molecular methods.
CONCLUSIONS: In general, the BRAF p.V600E variant exhibited a prominent prevalence in mixed and malignant odontogenic tumors. However, most of the findings are based on small cohorts of patients and further studies with larger cohorts are needed.
摘要：
背景：BRAFp.V600E基因变异通过触发肿瘤增殖和进展促进多种肿瘤的发病机制。这项研究的目的是分析BRAFp.V600E在良性混合上皮和间充质和恶性牙源性肿瘤中的患病率。此外,我们讨论了用于评估异常BRAF的不同检测方法。
方法：本系统综述遵循PRISMA指南，并在Prospero（CRD42023445689）注册。全面搜索PubMed/MEDLINE，Scopus,WebofScience,使用Embase电子数据库来回答以下问题：“良性混合和恶性牙源性肿瘤中BRAFp.V600E突变的患病率是多少？”使用JBI的关键评估工具评估了所选研究的方法学质量。
结果：最初，确定了387条记录，但只有11条符合纳入标准。共纳入70例良性混合上皮和间充质牙源性肿瘤和63例恶性牙源性肿瘤。我们发现BRAFp.V600E突变在混合肿瘤中的患病率为31.42％，在恶性牙源性肿瘤中的患病率为26.98％。此外，免疫组织化学显示与基于DNA的分子方法高度一致。
结论：一般来说，BRAFp.V600E变体在混合和恶性牙源性肿瘤中表现出突出的患病率。然而,大多数研究结果都是基于小的患者队列,需要对更大的队列进行进一步的研究.
方法：本系统综述遵循PRISMA指南，并在Prospero（CRD42023445689）注册。全面搜索PubMed/MEDLINE，Scopus,WebofScience,使用Embase电子数据库来回答以下问题：“良性混合和恶性牙源性肿瘤中BRAFp.V600E突变的患病率是多少？”使用JBI的关键评估工具评估了所选研究的方法学质量。
结果：最初，确定了387条记录，但只有11条符合纳入标准。共纳入70例良性混合上皮和间充质牙源性肿瘤和63例恶性牙源性肿瘤。我们发现BRAFp.V600E突变在混合肿瘤中的患病率为31.42％，在恶性牙源性肿瘤中的患病率为26.98％。此外，免疫组织化学显示与基于DNA的分子方法高度一致。
结论：一般来说，BRAFp.V600E变体在混合和恶性牙源性肿瘤中表现出突出的患病率。然而,大多数研究结果都是基于小的患者队列,需要对更大的队列进行进一步的研究.
